In particular, immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have become major pillars of systemic treatment for advanced NSCLC and are being increasingly applied in earlier stages of disease [1,4,5,6]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.